We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:

Search Results

Showing 1-20 of 1,865 results
  1. Lovastatin

    Reference work entry 2024
  2. Integrated Continuous Process Design for Crystallisation, Spherical Agglomeration, and Filtration of Lovastatin

    Purpose

    This work seeks to improve the particle processability of needle-like lovastatin crystals and develop a small-footprint continuous...

    Cameron J. Brown, John McGinty, ... Alastair J. Florence in Journal of Pharmaceutical Innovation
    Article Open access 01 March 2024
  3. Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling

    Background

    Lovastatin, an HMG-CoA inhibitor and an effective cholesterol lowering drug, exhibits anti-neoplastic activity towards several types of...

    Jian Gao, Jifen Hu, ... Yaacov Ben-David in BMC Cancer
    Article Open access 04 April 2023
  4. Suppressive role of lovastatin in intracerebral hemorrhage through repression of autophagy

    Statins possess critical function in the brain. Here, we intended to investigate the role of lovastatin in brain damage after intracerebral...

    **ong Deng, **mei Yang, ... Song Tian in Metabolic Brain Disease
    Article 28 October 2022
  5. Understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and in vivo

    Background

    The existence of the gut microbiota produces an “individual drug reaction.” As members of the intestinal microbiota, probiotics, although...

    Siyuan Shen, Jun Wang, ... Jiachao Zhang in Microbiome
    Article Open access 25 September 2023
  6. AGR2-induced cholesterol synthesis drives lovastatin resistance that is overcome by combination therapy with allicin

    Anterior gradient 2 (AGR2), a protein disulfide isomerase (PDI), is a multifunctional protein under physiological and pathological conditions. In...

    Nan Sheng, Yun-qiu Wang, ... Hui-qing Yuan in Acta Pharmacologica Sinica
    Article 22 April 2022
  7. Complex interactions of lovastatin with 10 chemotherapeutic drugs: a rigorous evaluation of synergism and antagonism

    Background

    Evidence bearing on the role of statins in the prevention and treatment of cancer is confounded by the diversity of statins,...

    Kaitlyn A. Khandelwal Gilman, Seungmin Han, ... Charles W. Putnam in BMC Cancer
    Article Open access 06 April 2021
  8. Design and Development of Solid SMEDDS and Liquisolid Formulations of Lovastatin, for Improved Drug Dissolution and In vivo Effects—a Pharmacokinetic and Pharmacodynamic Assessment

    Lovastatin (Lov) is a lipid-lowering agent, with 5% bioavailability (BA) due to extensive first pass metabolism and poor solubility. To enhance...

    Dinesh Suram, Kishan Veerabrahma in AAPS PharmSciTech
    Article 22 April 2022
  9. Autophagy inhibitors increase the susceptibility of KRAS-mutant human colorectal cancer cells to a combined treatment of 2-deoxy-D-glucose and lovastatin

    RAS-driven colorectal cancer relies on glucose metabolism to support uncontrolled growth. However, monotherapy with glycolysis inhibitors like...

    **ao-ming Huang, Jia-jun Huang, ... Wen-zhe Ma in Acta Pharmacologica Sinica
    Article 19 February 2021
  10. Novel compounds isolated from health food products containing beni-koji (red yeast rice) with adverse event reports

    Recently, health hazards, such as kidney damage, have been reported owing to the ingestion of a health food product, so-called “foods with functional...

    Seiji Tanaka, Naoko Masumoto, ... Michiho Ito in Journal of Natural Medicines
    Article 04 June 2024
  11. Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome

    Background

    The purpose of this study was to conduct a 20-week controlled trial of lovastatin (10 to 40 mg/day) in youth with fragile X syndrome (FXS)...

    Angela John Thurman, Laura A. Potter, ... Leonard Abbeduto in Journal of Neurodevelopmental Disorders
    Article Open access 22 April 2020
  12. Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study

    Purpose

    To investigate how statins reduce cardiovascular mortality in patients with type 2 diabetes (T2DM) in a dose-, class-, and use...

    Jung-Min Yu, Wan-Ming Chen, ... Szu-Yuan Wu in European Journal of Clinical Pharmacology
    Article 03 April 2023
  13. Biological Activities of Some Edible Mushrooms

    Since ancient times, mushrooms have been a valuable food source and traditional medicine worldwide. Edible mushrooms possess high nutritional value...
    Didem Şöhretoğlu, Ayşe Kuruüzüm-Uz in Mushrooms with Therapeutic Potentials
    Chapter 2023
  14. Neuroprotective effects of lovastatin in the pilocarpine rat model of epilepsy according to the expression of neurotrophic factors

    Studies have suggested that neurotrophic factors (NTFs) are involved in the status epilepticus development. This indicates their essential role in...

    Pooyan Moradi, Mahin Ganjkhani, ... Alireza Abdanipour in Metabolic Brain Disease
    Article 29 May 2019
  15. Kinome-wide analysis of the effect of statins in colorectal cancer

    Background

    Epidemiological studies and meta-analyses show an association between statin use and a reduced incidence of colorectal cancer (CRC). We...

    Sarah Ouahoud, Rutger J. Jacobs, ... James C. H. Hardwick in British Journal of Cancer
    Article 19 March 2021
  16. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression

    Background

    The use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) brings remarkable benefits for the survival of patients...

    Zhenzhen Pan, Kai Wang, ... Xuansheng Ding in Molecular Cancer
    Article Open access 18 March 2022
  17. Combining familial hypercholesterolemia and statin genetic studies as a strategy for the implementation of pharmacogenomics. A multidisciplinary approach

    The diagnostic process of familial hypercholesterolemia frequently involves the use of genetic studies. Patients are treated with lipid-lowering...

    Luis Ramudo-Cela, Sara Santana-Martínez, ... Lorenzo Monserrat-Iglesias in The Pharmacogenomics Journal
    Article 31 March 2022
  18. Diagnosis and Drug Prediction of Parkinson’s Disease Based on Immune-Related Genes

    Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Immune mechanisms play an important role in the development of PD. The...

    **glei Bao, Wansheng Chang, Yanjun Zhao in Journal of Molecular Neuroscience
    Article 22 June 2022
  19. Evaluation of Piperine as Natural Coformer for Eutectics Preparation of Drugs Used in the Treatment of Cardiovascular Diseases

    Piperine (PIP) was evaluated as a natural coformer in the preparation of multicomponent organic materials for enhancing solubility and dissolution...

    Krissia Wilhelm-Romero, María Isabel Quirós-Fallas, ... Andrea Mariela Araya-Sibaja in AAPS PharmSciTech
    Article 26 April 2022
Did you find what you were looking for? Share feedback.